Jodie Morrison, Q32 Bio CEO

November 16, 2023 08:44 AM ESTUpdated 03:01 PM

Q32 Bio to take Homology Medicines’ Nasdaq spot to fund PhII trials in autoimmune, inflammatory conditions

Kyle LaHucik

Biotech Correspondent

The reverse mergers are flowing. Q32 Bio will take Homology Medicines’ place on the Nasdaq, the companies said Thursday …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

HHS says it's pulled Covid shot guidance for healthy kids. The CDC vaccine schedule shows otherwise

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

Vertex touts promising first few months of launch for non-opioid pain drug Journavx

Vertex's next challenge for pain pill? Cracking a market dominated by cheap opioids

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation